Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme

AIDS

Volumn 24, Issue SUPPL. 5, 2010, Pages

  Charalambous, Salome ^a   Grant, Alison D ^b   Innes, Craig ^a   Hoffmann, Christopher J ^a,c   Dowdeswell, Rob ^d   Pienaar, Jan ^e   Fielding, Katherine L ^b   Churchyard, Gavin J ^a,b,f  

^a AURUM INSTITUTE   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Anglo Platinum South Africa   (South Africa)

^e Anglo Coal Highveld Hospital   (South Africa)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

antiretroviral therapy; isoniazid; mortality; South Africa; workplace

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ISONIAZID; LAMIVUDINE PLUS ZIDOVUDINE; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; WORKPLACE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; ISONIAZID; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SOUTH AFRICA; TUBERCULOSIS; VIRAL LOAD; WORKPLACE;

EID: 78649289257     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000391010.02774.6f     Document Type: Article

References (36)

1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
2. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an anti-retroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
3. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7:1569-1579.
4. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS 1997; 11 (Suppl B):S43-54.
5. Badri M, Wilson D, Wood R. Effect of highly active antiretro-viral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-2064.
6. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-333.
7. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10:489-498.
8. Saraceni V, King BS, Cavalcante SC, Golub JE, Lauria LM, Moulton LH, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2008; 12:769-772.
9. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
10. Innes C, Charalambous S, Pemba LF, Bogoshi M, Steele J, Senoge S, et al. Causes of mortality in patients on antiretroviral therapy in South Africa [published abstract CDC0001]. In: XVI International AIDS Conference; Toronto, Canada; 2006.
11. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
12. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004:CD000171.
13. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev:CD000171.
14. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293:2719-2725.
15. Organization WHO. WHO 3 I's Meeting. Report of a Joint HIV/ AIDS and TB department Meeting. In: World Health Organization; 2008. http://www.who.int/hiv/ pub/tb/3is-mreport/en/ index.html. [Accessed 5 September 2010].
16. Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196 (Suppl 1):S52-62.
17. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-1258.
18. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant AD. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int J Tuberc Lung Dis 2007; 11:1232-1236.
19. Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, et al. Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007; 19:34-41.
20. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-2147.
21. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
22. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
23. Bucher H. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501-507.
24. Golub JE, Chaisson RE, Martinson NA. Additive effects of isoniazid preventive therapy and HAART. AIDS 2009; 23: 1446-1447.
25. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
26. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448.
27. World Health Organization. Global tuberculosis control 2009. Epidemiology, strategy, financing. Geneva: World Health Organization; 2009. WHO/HTM/TB/2009.411. http:// www.who.int/tb/publications/global-report/2009/en/ index.html WHO/HTM/TB/2009.411 [Accessed 5 September 2010].
28. Hiransuthikul N, Hiransuthikul P, Nelson KE, Jirawisit M, Paewplot R, Kasak S. Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand. Southeast Asian J Trop Med Public Health 2005; 36:1208-1215.
29. Lester R, Hamilton R, Charalambous S, Chandler C, Churchyard GJ, Grant AD. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study in South Africa. In: 2nd SA TB conference. Durban, South Africa; 2010. [Abstract 208, oral presentation]
30. Murray J, Sonnenberg P, Nelson G, Bester A, Shearer S, Glynn JR. Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners. AIDS 2007; 21 (Suppl 6):S97-S104.
31. Charalambous S, Morris C, Innes C, Shisana M, Churchyard GJ, Grant AD, et al. TB incidence in HIV-infected patients starting antiretroviral therapy in a South African mining population. In: 39th World ConferenceonLung Healthofthe International Union Against Tuberculosis and Lung Disease; Paris, France; 2008.
32. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-2457.
33. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-808.
34. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11:875-882.
35. Gideon HP, du Toit E, Maartens G. Evaluation of IGRA for detection of prevalent tuberculosis (TB) amongst asymptomatic HIV-1 infected adults on combined antiretroviral treatment (ART) being screened for a TB prevention study in Khayelitsha, South Africa. In: 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 2009.
36. ClinicalTrials.gov. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). http://clinicaltrials.gov/ct2/show/ NCT00495651. [Accessed 28 January 2010].